Review

Consensus recommendations on Epilepsy in Phelan-McDermid syndrome

Irenaeus F.M. de Coo a,*, Sarah Jesse b, Thuy-Linh Le c, Carlo Sala d, The European Phelan-McDermid syndrome consortium e

a Department of Toxicogenomics, Unit Clinical Genomics, Maastricht University, MHeNs School for Mental Health and Neuroscience, Maastricht, the Netherlands
b Department of Neurology, University of Ulm, Ulm, Germany
c Human Genetics and Cognitive Functions, Institut Pasteur, Université de Paris, Paris, France
d CNR Neuroscience Institute, Milano, Italy
e University Medical Centre Groningen, the Netherlands

ARTICLE INFO
Handling Editor: A. Verloes
Keywords:
Phelan-McDermid syndrome
Epilepsy
Regression
Electroencephalogram
Brain-MRI

ABSTRACT

Phelan-McDermid syndrome (PMS) is a 22q13.3 deletion syndrome that presents with a disturbed development, neurological and psychiatric characteristics, and sometimes other comorbidities like seizures. The epilepsy manifests itself in a variety of seizure semiologies. Further diagnostics using electroencephalogram (EEG) and brain magnetic resonance imaging (MRI) are important in conjunction with the clinical picture of the seizures to decide whether anticonvulsant therapy is necessary. As part of the development of European consensus guidelines we focussed on the prevalence and semiology of epileptic seizures in PMS associated with a pathogenic variant in the SHANK3 gene or the 22q13 deletion involving SHANK3, in order to then be able to make recommendations regarding diagnosis and therapy.

1. Introduction

This paper has been written as part of a European consensus guideline in Phelan-McDermid syndrome (PMS). The focus in this publication is on epilepsy in SHANK3-related PMS due to the presence of a pathogenic variant in SHANK3 or a deletion of chromosome 22q13.3 including the SHANK3 gene (Phelan et al., 2022). PMS presents with a developmental disorder with neurological and psychiatric symptoms sometimes accompanied by seizures (Schön et al., 2023). Epilepsy occurs relatively frequent in PMS. The prevalence of fever-related and non-fever-related seizures in patients with PMS is 20–30% (Kolevzon et al., 2014), but the life-time risk is more than 60% at adult age ( Sarasua et al., 2014) and is reviewed in Holder and Quach (2016). Atypical absences are the most common type of seizures in PMS and are not always easy to detect. It is therefore important to be alerted on this high risk for the patient to present epileptic seizures, to train parents in semiology and to carry out an electroencephalogram (EEG), if there is any suspicion. It is desirable to start therapy early.

2. Methods

Based on the use of the AGREE II methodology and on bottleneck analysis carried out by the guideline working group and the results of the survey of patient representatives (Landlust et al., 2023), the following key questions have been formulated.

- What is the prevalence of epilepsy in PMS, and is there a specific type of epilepsy?
- What is the mechanism underlying epilepsy in PMS?
- What is the treatment for epilepsy in PMS?

We performed a general scientific literature search in the Pubmed database, using the following search terms: phelan-mcdermid syndrome AND (epilepsy OR seizure). For the EU Guidelines, there were 33 articles published between 01/01/2013 and 31/12/2020 that met the search criteria. Since then, 12 publications (including 5 reviews) have been published before September 2022. The literature was then selected and sorted based on the predetermined key questions.

For the questions regarding the prevalence, types, and mechanisms of epilepsy in PMS, the following articles were included: Lund et al. * Corresponding author.
E-mail addresses: rene.decoo@maastrichtuniversity.nl (I.F.M. de Coo), sarah.jesse@uni-ulm.de (S. Jesse), thuy-linh.le@inserm.fr (T.-L. Le), carlo.sala@in.cnr.it (C. Sala).

https://doi.org/10.1016/j.ejmg.2023.104746
Received 6 December 2022; Received in revised form 10 March 2023; Accepted 18 March 2023
Available online 24 March 2023
1769-7212/© 2023 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
European Journal of Medical Genetics 66 (2023) 104746

3. Results

3.1. Review of the literature

3.1.1. Prevalence of epilepsy in PMS

The prevalence of epilepsy in PMS ranges from 17% to 70% (reviewed in Holder and Quach, 2016). The great differences in the studies available for PMS are due to different inclusion criteria and to the number of patients included. In the largest cohort of patients with PMS (n = 201), the prevalence of any type of seizures was 27%, with a significant increase with age: 11% under 5 years of age, 26% between 5 and 10 years old, 43% between 10 and 18 years old and 60% over the age of 18. (Sarasua et al., 2014). This study indicates that the life-time prevalence is high (>60%) and that age at onset for epilepsy can be different from one PMS patient to another.

In a study of 32 individuals with PMS (age from 1.6 to 45.4 years, mean = 8.8, SD = 9.2), parents report seizures in 41%, of whom 22% had febrile seizures, 13% had non-febrile seizures and 6% had both. (Soorya et al., 2013). The non-febrile seizures include generalized and focal seizures and have proven EEG abnormalities. Notably, 13% of the individuals in this study have EEG abnormalities but no clinical seizures (Soorya et al., 2013). Thus, in PMS, epileptiform discharges in EEG can be seen in PMS-patients with or without clinical manifestations of epilepsy.

In another study of 24 individuals with PMS (age from 2 to 28 years), 11 individuals (46%) have at least one seizure, with variable age of onset (1-14 years, mean 5.2 years) (Holder and Quach, 2016). The most frequent type of seizure is atypical absences (90%). Other types of seizure are also observed, including tonic (54%), atonic (18%), tonic-clonic (9%), and myoclonic (9%) (Holder and Quach 2016). Six (54%) have a combination of seizure types, and five (20%) have a status epileptics. EEG findings include abnormally slow or absent occipital dominant rhythm (42%), focal spike and slow wave discharges (38%), and generalized spike and slow wave discharges (19%). Brain magnetic resonance imaging (MRI) shows anomalies of the corpus callosum (29%) and T2-weighted hyperintensities of the deep white matter (24%). However, there is to date no specific EEG abnormalities or structural abnormalities detected by brain MRI that can inform on the occurrence and/or types of epilepsy, or on pharmacoresistance (Holder and Quach 2016). A group of 14 patients with PMS and seizures have been investigated (Jesse et al., 2021) by means of high-resolution MRI with subsequent automatic morphometric MRI postprocessing analysis. Also, in this group no subtle cortical malformations explaining the epilepsy are detected.

In a cohort of 16 patients with PMS, including 7 with a diagnosis of epilepsy and 9 without clinical seizures, an overnight EEG leads to an increase in the detection of epileptiform activity to 75% (12 of 16 patients), compared to 18.75% (3 of 16 patients) detected by routine EEG (Khan et al., 2018). In cases where EEG analysis has failed to delineate the clinical condition, overnight prolonged video-EEG monitoring can be carried out to increase the probability of detection of epileptiform activity (Wilmshurst J et al., 2015). In accordance with previous observations by Holder and Quach, the EEG findings are highly variable (i.e. non-specific sharps, sharp and slow wave discharges, spike, polyspike and slow wave discharges), which is not specific to any type of seizures (i.e. focal, multifocal, and generalized) (Khan et al., 2018).

The relationship between epilepsy and regression has been investigated in a group of 50 patients with PMS (Reierson et al., 2017). While a significantly higher risk of seizures is reported in patients with abnormal EEG (OR = 24.661, p = 0.005), neither seizures nor EEG abnormalities are associated with regression (p > 0.223) (Reierson et al., 2017). As for epilepsy, to date, there are no clinical or biological markers known to help understand or predict the regression and or psychiatric illness in patients with PMS (Kohlenberg et al., 2020).

3.1.2. Mechanism underlying epilepsy in PMS

The mechanism underlying epilepsy in PMS remains largely unknown and might be different from one patient to another. In cultures of neurons derived from iPSC from PMS patients the cell type composition is slightly different compared to their unaffected siblings, with an increase of excitatory neurons proportion as well as a reduction of inhibitory neurons proportion (Breen et al., 2020). Shank3 knockout mice do not display epileptic seizures, however abnormal EEG (Yoo et al., 2019 jun) and increased excitation in some brain circuits have been described (Yoo et al., 2019 oct; Lee et al., 2015; Ahn et al., 2020; Chen et al., 2020). All these data suggest that loss or reduced levels of the SHANK3 protein might cause an increased excitation in the brain caused by a reduced function of the inhibitory neurons.

In a cohort of patients carrying deleterious SHANK3 point mutations (16 between 3 and 15 yr and 1 at 42 yr), 5 out of 17 (29%) present with seizures, suggesting that, within the 22q13 region, SHANK3 pathogenic variants or SHANK3 haploinsufficiency might be risk factors for seizures (De Rubeis et al., 2018).

Different types of seizures are documented in patients carrying SHANK3 pathogenic variants, including febrile, absence, focal, and generalized seizures, which can occur in combination. Like other PMS cases, EEG abnormalities are not observed in patients with SHANK3 pathogenic mutations either with or without clinical seizures. Meanwhile, brain structural MRI showed white matter abnormalities in 3 (17.6%) patients, including 1 with leukodystrophy. In the same cohort, it should be noted that most patients with SHANK3 point mutations did not present with seizures (De Rubeis et al., 2018), suggesting that in addition to SHANK3, other genetic and/or environmental factors may increase the risk of epilepsy in patients with PMS.

The size of the 22q13 deletion has been shown to be associated with a history of abnormal EEG, but not with the risk for epilepsy (Sarasua et al., 2014; Reierson et al., 2017; Tabet et al., 2017). Further analyses of
patients with a 22q13 deletion and epilepsy led to the identification of additional copy-number variants (CNVs) that cover susceptibility genes for epilepsy, including KCNT1, MYT1L, DEAF1 and SLC25A22, suggesting a polygenic/multifactorial model underlying the presence of epilepsy in patients with PMS (Tabet et al., 2017).

(Jain et al., 2022) investigated 57 individuals for the prevalence of seizures and the association with genetic and metabolic features. Among the participants, 46% have seizures with the most common type being absence and tonic-clonic seizures. They proposed the TBC1D22A gene as a susceptibility gene for epilepsy in addition to SHANK3. A metabolic profile, suggesting a disrupted utilization of main energy sources, could be more frequent in PMS patients with epilepsy.

Metachromatic leukodystrophy (MLD) is a rare hereditary disease caused by recessive mutations of the ARSA gene on chromosome 22q13. MLD is characterized by the accumulation of fats called sulfatides, causing the destruction of the protective fatty layer (myelin sheath) surrounding the nerves in both the central nervous system and the peripheral nervous system. Heterozygous carriers of a pathogenic variant in ARSA are healthy, however MLD symptoms have sporadically been reported in individuals with PMS (De Ruheis et al., 2018). The ARSA gene is involved in the 22q13 deletion in 77% of PMS patients (not a causative factor for MLD on its own) and has been proposed to be a risk factor for regression (Kolevzon et al., 2019, al., 2020, Minghunjerdsuk et al., 2021). The heterozygous ARSA deletion, in addition to a second ARSA genetic variant on the non-deleted chromosome, (gene frequency of this pseudodeficiency allele at the ARSA locus is 13.7 – 17%), might also contribute to the risk of seizures.

Brain-MRI investigations can detect other epileptogenic brain malformations that might have contributed to the epilepsy and or regression in PMS. These include – posterior fossa malformations, unilateral opercular polymicrogyria, bilateral and perisylvian polymicrogyria (Aldinger et al., 2013; Papetti et al., 2017; Kurras et al., 2018).

In summary, within the 22q13 region, the loss of the SHANK3 gene represents a risk factor for epilepsy. SHANK3 haploinsufficiency might alter the excitation/inhibition balance or utilization of energy sources in specific brain circuits, but other genetic or environmental factors might be required to provoke seizures. The multifactorial model of epilepsy in PMS might explain why the risk and the type of epilepsy and the effective treatments for reducing seizures can be different from one individual to another.

3.2. Treatment of epilepsy in PMS

A wide range of antiepileptic drugs has been used to treat epilepsy in PMS, including lamotrigine, levetiracetam, topiramate, rufinamide, zonisamide, perampanel, felbamate, valproate, carbamazepine, oxcarbazepine, lacasamide, phytoin, methsuximide, ethosuximide, chlorzepeate, lorazepam, and phenobarbital (Figuera et al., 2014; Ishikawa et al., 2016; Cortés-Saladelafont et al., 2016, et al., 2016, Holder and Quach, 2016). No antiepileptic drug has shown to be more efficient than others to treat epilepsy in PMS (Holder and Quach, 2016). Nevertheless, most cases respond well to one drug with a decreased frequency of seizures and improvement in behavior (Figuera et al., 2014; Ishikawa et al., 2016; Cortés-Saladelafont et al., 2016, et al., 2016, Holder and Quach, 2016). Patients suffering from multiple types of seizures are more likely to require a combination of two or more medications (Holder and Quach, 2016). A few individuals develop severe epileptic encephalopathy, such as Lennox-Gastaut syndrome, with pharmacoresistant epilepsy (Landlust et al., 2023; Soorya et al., 2013, Ishikawa et al., 2016; Holder and Quach, 2016). Some patients are treated by temporal lobectomy (no further details provided), or implantation of a vagus nerve stimulator with a modest diminution in seizure frequency (Soorya et al., 2013; Holder and Quach, 2016). Based on these data, anticonvulsant therapy shall be given according to local guidelines.

4. Discussion

The pooled prevalence of seizures in PMS calculated from 14 unique studies is 32% (Holder and Quach, 2016), but the life-time prevalence at adult age can be up to 60%. It seems that there is no developmental period which is more at risk for the first seizure events. All types of seizures, both febrile and non-febrile, can occur in individuals with PMS. The most frequently occurring type are atypical absences. Other seizure types cover tonic, atonic, tonic-clonic and myoclonic semiology.

In PMS the prevalence of epilepsy and comorbidities like learning disabilities, mental health issues, and sleep disorders is relatively high (Ho et al., 2018). A change in sleep pattern might point to the presence of seizures (Landlust et al., 2023).

EEG abnormalities can be present in individuals with PMS with and without seizures. The EEG findings are not specific; the most seen pattern is a slow background pattern. Deletion of SHANK3 increases the risk for all type of seizures, irrespective the size of the deletion. Larger deletion sizes are associated with a history of abnormal EEG. EEG abnormalities and seizures are not associated with an increased risk for regression. The response to anticonvulsant treatment in individuals with PMS is not different from patients with epilepsy without PMS.

Brain imaging, preferably MRI, is indicated in every individual with PMS who shows neurological signs and symptoms, including seizures (Wang et al., 2020). Given that epilepsy occurs with and without overt clinical manifestations in patients with PMS with a higher risk with increasing age, it is a concern. There are both, fever-related and non-febrile seizures, generalized and focal seizures. At clinical manifestation, the epilepsy shall be evaluated. In a minority of individuals with PMS, epilepsy develops into a pharmaco-resistant form. There is no evidence that individuals with PMS benefit from a specific pharmacotherapeutic treatment for seizures. Based on these data, anticonvulsant therapy should be given according to local guidelines.

Funding

ERN-ITHACA is partly co-funded by the Health Programme of the European Union. This work was funded by Institut Pasteur, the Bettencourt-Schueller Foundation, Université Paris Cité, the Eranet-Neuron (ALTRUISM), the GenMed Labex, and the Inception program (Investissement d’Avenir grant ANR-16-CONV-0005). This project received funding from the European Union’s Horizon 2020 research and innovation programmes under CANDY grant agreement N° 847818 and under the EJP RD COFUND-EJP N° 825575.

The views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.

CRediT authorship contribution statement

Ireneaus F.M. de Coo: Conceptualization, Methodology, Investigation, Writing – original draft, Writing – review & editing. Sarah Jesse: Investigation, Data curation, Writing – review & editing. Thuy-Linh Le: Investigation, writing editing. Carlo Sala: Investigation, writing editing. Thomas Bourgeron: Conceptualization, Funding acquisition.

Data availability

Data will be made available on request.

Acknowledgements

This project has been supported by European Reference Network on Rare Congenital Malformations and Rare Intellectual Disability (ERN-ITHACA).